Reuters logo
RPT-Sanofi wins U.S. OK for short needle flu vaccine
May 10, 2011 / 6:36 AM / 6 years ago

RPT-Sanofi wins U.S. OK for short needle flu vaccine

(Repeats to attach to Reuters alert)

PARIS, May 10 (Reuters) - French drugmaker Sanofi Aventis (SASY.PA) said on Tuesday it had won U.S. approval to market its Fluzone Intradermal vaccine for adults, allowing for flu injections with a very fine needle.

Sanofi has said that the new vaccine, developed with syringe maker Becton Dickinson (BDX.N), may hurt less than standard vaccines, does a better job of stimulating protection against influenza and requires less of the active ingredient.

Most adult flu vaccines are given using a needle 1 inch to 1.5 inches (25 mm to 40 mm) long that goes into muscle tissue.

Sanofi’s new needle is one-tenth that long, just 1.5 mm, and the vaccine uses one-fifth the usual amount of the active ingredient, called antigen.

The Fluzone Intradermal vaccine will be available to healthcare providers in the U.S. for the 2011-2012 flu season, Sanofi said in a statement. (Reporting by Caroline Jacobs, Editing by Christian Plumb)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below